Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 207

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 207
---
 ASU 2016-13 didn’t have material effect on its consolidated financial statements and related disclosures.

In December
2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting
for income taxes by removing a variety of exceptions within the framework of ASC 740. These exceptions include the exception to the incremental
approach for intraperiod tax allocation in the event of a loss from continuing operations and income or a gain from other items (such
as other comprehensive income), and the exception to using general methodology for the interim period tax accounting for year-to-date
losses that exceed anticipated losses.

<div align='center'>F-20</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

NOTE 3 – ACQUISITION

The Company accounted for the following
transaction as a business combination and allocated the purchase consideration to assets acquired and liabilities assumed based on their
estimated fair values.

On November 14, 2023, the Company entered
into the Stock Exchange Agreement (the “Share Exchange Agreement”) with Predecessor.(formerly known as LipoVac Ltd), an Israeli
company (“LipoVation”) and the shareholders of Predecessor pursuant to which the former shareholders of LipoVation have agreed
to contribute all of their shareholdings in Predecessor in exchange for the right to receive shares of the Company’s common stock.
On July 23, 2024, the transactions contemplated under the Stock Exchange Agreement were closed and as a result Predecessor became a wholly
owned subsidiary of the Company.

In consideration for the contribution
of all of their shareholdings in Predecessor to the Company, the Company issued to the former Predecessor shareholders an aggregate of
23,171,642 restricted shares of the Company’s common stock, representing 40% of the outstanding shares of the Company immediately
following the closing.

The company has calculated the fair
value of the Consideration shares based on the price of transactions close to the acquisition date. The Company didn’t use quoted
market prices of Revium RX due to the negligible volume of trading in its shares with no records of trading close to the transaction
date.

Revium RX is a public company whose
common stock is listed on the over the counter market in the U.S. (OTC Market LLC) and due